KLK3 and prostate carcinoma: During the early-to-mid 1990s, prostate cancer mortality declined in the US and UK following the advent of PSA testing and RP as a curative measure for localised disease.5,6,10,15 After an initial spike, the US prostate cancer incidence rate decreased concurrently with declining mortality as the UK incidence rate continued to rise.